![Dov Elefant](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 44 688 $ al 31/07/2026
Dov S.
Elefant currently works at Femasys, Inc., as Chief Financial Officer from 2022.
Mr. Elefant also formerly worked at Tetragenex Pharmaceuticals, Inc., as Director-Accounting & Finance from 1999 to 2007, Synvista Therapeutics, Inc., as Assistant Controller from 1998 to 1999, Celsus Therapeutics Plc, as Chief Operating & Financial Officer from 2013 to 2015, Althera Medical Ltd., as Chief Financial Officer, Lev Pharmaceuticals, Inc., as Controller from 2007 to 2009, EpiCept Corp., as Controller, VP-Finance & Administration from 1999 to 2007, Cellectar Biosciences, Inc., as Chief Financial Officer & Vice President from 2019 to 2022, and Akari Therapeutics Plc, as Chief Financial Officer from 2012 to 2019.
Mr. Elefant received his undergraduate degree from Sy Syms School of Business.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
FEMASYS, INC. 0,52 % | 07/08/2026 | 15.625 ( 0,52 % ) | 44 688 $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| FEMASYS INC. | Director Financiero/CFO | 28/02/2022 |
| Empresas | Cargo | Fin |
|---|---|---|
| CELLECTAR BIOSCIENCES, INC. | Director Financiero/CFO | 23/02/2022 |
| AKARI THERAPEUTICS, PLC | Director Financiero/CFO | 15/09/2019 |
Althera Medical Ltd.
 Althera Medical Ltd. Medical SpecialtiesHealth Technology Develops therapeutic devices for the treatment of various cancers | Director Financiero/CFO | - |
Lev Pharmaceuticals, Inc.
 Lev Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutic products for the treatment of inflammatory diseases | Comptroller/Controller/Auditor | 01/02/2009 |
EpiCept Corp.
 EpiCept Corp. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer and pain | Director Financiero/CFO | 01/03/2007 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 10 |
|---|---|
Synvista Therapeutics, Inc.
 Synvista Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for diseases of cardiovascular aging and diabetes complications | Health Technology |
Celsus Therapeutics Plc
 Celsus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Develops novel non steroidal anti-inflammatory drugs | Health Technology |
Femasys, Inc.
 Femasys, Inc. Electronic Equipment/InstrumentsElectronic Technology Operates as a medical device company that focuses on women''s healthcare | Electronic Technology |
Tetragenex Pharmaceuticals, Inc.
 Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and commercializes antibiotics | Health Technology |
Althera Medical Ltd.
Althera Medical Ltd. Medical SpecialtiesHealth Technology Develops therapeutic devices for the treatment of various cancers | Health Technology |
Lev Pharmaceuticals, Inc.
Lev Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutic products for the treatment of inflammatory diseases | Health Technology |
EpiCept Corp.
EpiCept Corp. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer and pain | Health Technology |
Cellectar Biosciences, Inc.
 Cellectar Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that is engaged in developing compounds for the treatment and imaging of cancer | Health Technology |
Sy Syms School of Business
 Sy Syms School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Akari Therapeutics Plc
 Akari Therapeutics Plc BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapies for autoimmune and inflammatory diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
